Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Epilepsy
Interventions: Memantine, Sugar Pill; Drug · Other
Lead sponsor: American Academy of Neurology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Newton, Massachusetts

Conditions: Inflammatory Bowel Diseases
Interventions: Biofeedback Enhanced Treatment; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Coronary Artery Disease
Interventions: Prasugrel, Ticagrelor; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 74 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Progressive Familial Intrahepatic Cholestasis
Interventions: A4250 (odevixibat); Drug
Lead sponsor: Albireo, an Ipsen Company; Industry
Eligibility: 0 Months to 100 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: Furosemide (loop diuretic) Tablets; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Carrboro, North Carolina • Pittsboro, North Carolina • Sanford, North Carolina + 1 more

Conditions: Parkinson Disease
Interventions: Training with HWA device, Usual Care; Device · Other
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 1 Month to 12 Months
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more

Conditions: Hypertension
Interventions: Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: HIV Infections, Alcohol Use Disorder, Violence, Gender-Based
Interventions: PrEP for WINGS, PrEP Decision Aid; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: OA-PCP Intervention, Attention Control; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diverticulitis
Interventions: Mesalamine, Probiotic, Placebo, Dietary Advice, Antibiotic for Diverticulitis; Drug · Other
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 36
States / cities: Tucson, Arizona • Los Angeles, California • Merced, California + 33 more

Conditions: Pediatric Asthma
Interventions: School-Based Telemedicine Enhanced Asthma Management, Enhanced Usual Care; Other
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 10 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: Rigosertib Sodium, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stress, Fatigue, Anxiety
Interventions: Massage; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy; Procedure · Radiation · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetic Peripheral Neuropathy
Interventions: Acupuncture; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes
Interventions: AZD0186, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cannabis Use, Cannabis Dependence, Cannabis Use Disorder, Cannabis Abuse, Cannabis Intoxication, Cannabis Smoking, Cannabis Withdrawal, Cannabis-Related Disorder, Cannabis Abuse, in Remission, Cannabis Abuse, Episodic Use, Marijuana, Marijuana Abuse, Marijuana Use, Marijuana Smoking, Marijuana Dependence, Marijuana User, Marijuana-Related Disorder, Marijuana Use Disorder, Addiction, Addiction, Substance, Substance Use, Substance Use Disorders, Substance Dependence, Substance Abuse, Substance Related Problem, Substance Abuse Drug Chronic
Interventions: Contingency Management, Elastic Net Regression; Behavioral · Device
Lead sponsor: Indiana University; Other
Eligibility: 14 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV, Mental Health Issue
Interventions: Tell Me More ("Dime Mas"), Peer Ambassador Stories [Listen Miami ("Oye Miami")], Standard Community Outreach; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Schizophrenia
Interventions: Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone; Other · Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 34
States / cities: Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more

Conditions: Schizophrenia, Nicotine Dependence
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Human Immunodeficiency Virus, HIV Infections
Interventions: CHIMES Intervention, Standard of Care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hepatocellular Carcinoma
Interventions: TheraBionic, Regorafenib; Device · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

Heart Rate Variability and Inflammatory Bowel Disease

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

Robotic Walking Device to Improve Mobility in Parkinson's Disease

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

An Effectiveness Trial of the PrEP for WINGS Study

Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP) (R33)

Asacol Acute Diverticulitis(DIVA)Study

School-Based Telemedicine Enhanced Asthma Management

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Measuring the Effect of Therapeutic Massage on Pain and Discomfort in Cardiac Cath Lab Staff

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Group Acupuncture Treatment Effects for Painful Diabetic Neuropathy (GATE-PDN)

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

Neuroimaging of Adolescent Cannabis Use Treatment

Tell Me More ("Dime Mas")

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia

Cross-disciplinary HIV Integrated Mental Health Support Intervention

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib